LRRC4C

Summary

LRRC4C (leucine rich repeat containing 4C, HGNC:29317) is a protein-coding gene on chromosome 11p12, encoding Leucine-rich repeat-containing protein 4C (Q9HCJ2). May promote neurite outgrowth of developing thalamic neurons.

NGL1 is a specific binding partner for netrin G1 (NTNG1; MIM 608818), which is a member of the netrin family of axon guidance molecules (Lin et al., 2003 [PubMed 14595443]).

Source: NCBI Gene 57689 — RefSeq curated summary.

At a glance

• GWAS associations: 26
• Clinical variants (ClinVar): 70 total
• MANE Select transcript: NM_001258419

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29317
Approved symbol	LRRC4C
Name	leucine rich repeat containing 4C
Location	11p12
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1580, NGL-1
Ensembl gene	ENSG00000148948
Ensembl biotype	protein_coding
OMIM	608817
Entrez	57689

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 18 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000278198, ENST00000527150, ENST00000528697, ENST00000530763, ENST00000533474, ENST00000534577, ENST00000901039, ENST00000901040, ENST00000901041, ENST00000901042, ENST00000901043, ENST00000901044, ENST00000966813, ENST00000966814, ENST00000966815, ENST00000966816, ENST00000966817, ENST00000966818, ENST00000966819

RefSeq mRNA: 2 — MANE Select: NM_001258419 NM_001258419, NM_020929

CCDS: CCDS31464

Canonical transcript exons

ENST00000528697 — 7 exons

Exon	Start	End
ENSE00002147701	41459431	41459652
ENSE00002149688	40648142	40648278
ENSE00002162752	40140801	40140853
ENSE00002177887	40933635	40933723
ENSE00002197708	40319628	40319721
ENSE00002199337	40241519	40241598
ENSE00003844302	40114209	40116334

Expression profiles

Bgee: expression breadth ubiquitous, 206 present calls, max score 96.78.

FANTOM5 (CAGE): breadth broad, TPM avg 1.6277 / max 244.0114, expressed in 230 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
119412	0.5157	134
119406	0.3103	105
119413	0.2182	80
119407	0.1484	69
119405	0.1137	68
119402	0.1096	52
119414	0.0828	50
119403	0.0677	37
119401	0.0402	14
119404	0.0213	10

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	96.78	gold quality
buccal mucosa cell	CL:0002336	96.04	gold quality
Brodmann (1909) area 23	UBERON:0013554	95.86	gold quality
Brodmann (1909) area 46	UBERON:0006483	95.74	gold quality
entorhinal cortex	UBERON:0002728	95.22	gold quality
postcentral gyrus	UBERON:0002581	94.51	gold quality
parietal lobe	UBERON:0001872	94.48	gold quality
superior frontal gyrus	UBERON:0002661	94.25	gold quality
ventral tegmental area	UBERON:0002691	92.46	gold quality
superior vestibular nucleus	UBERON:0007227	92.01	gold quality
occipital lobe	UBERON:0002021	91.82	gold quality
lateral globus pallidus	UBERON:0002476	91.66	gold quality
primary visual cortex	UBERON:0002436	91.57	gold quality
medulla oblongata	UBERON:0001896	91.53	gold quality
substantia nigra pars reticulata	UBERON:0001966	90.47	gold quality
temporal lobe	UBERON:0001871	89.32	gold quality
trigeminal ganglion	UBERON:0001675	88.72	gold quality
frontal cortex	UBERON:0001870	88.55	gold quality
substantia nigra pars compacta	UBERON:0001965	88.55	gold quality
prefrontal cortex	UBERON:0000451	88.35	gold quality
neocortex	UBERON:0001950	87.76	gold quality
subthalamic nucleus	UBERON:0001906	87.70	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	87.60	gold quality
cerebral cortex	UBERON:0000956	87.52	gold quality
dorsal plus ventral thalamus	UBERON:0001897	87.40	gold quality
endothelial cell	CL:0000115	87.39	silver quality
dorsal root ganglion	UBERON:0000044	87.15	gold quality
corpus callosum	UBERON:0002336	86.88	gold quality
pons	UBERON:0000988	86.69	gold quality
inferior vagus X ganglion	UBERON:0005363	86.32	gold quality

Single-cell (SCXA)

Detected in 6 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	7201.35
E-HCAD-30	yes	7035.07
E-GEOD-180759	yes	5760.13
E-HCAD-25	yes	5505.16
E-GEOD-84465	yes	298.34
E-ANND-3	no	5.63

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

31 targeting LRRC4C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-4782-3P	99.88	73.31	735
HSA-MIR-6766-3P	99.88	73.38	732
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-4760-5P	99.80	69.88	1619
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-8061	99.63	69.44	1411
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-513A-3P	99.39	70.63	3620
HSA-MIR-513C-3P	99.39	70.63	3620
HSA-MIR-3606-3P	99.11	69.84	3254
HSA-MIR-936	98.87	70.51	1124
HSA-MIR-508-3P	98.66	69.62	887
HSA-MIR-599	98.32	66.99	1037
HSA-MIR-4445-5P	97.21	66.16	832
HSA-MIR-4288	97.11	67.23	1636
HSA-MIR-5694	97.06	67.70	682
HSA-MIR-346	97.01	66.97	662
HSA-MIR-597-5P	96.82	67.57	732
HSA-MIR-616-3P	96.82	66.99	784
HSA-MIR-592	96.59	67.59	817
HSA-MIR-632	96.08	67.17	798

Literature-anchored findings (GeneRIF, showing 4)

• NGL-1 is most abundant in the striatum and the cerebral cortex–the intermediate and final targets, of thalamocortical axons; surface-bound NGL-1 stimulates, but soluble NGL-1 disrupts, the growth of embryonic thalamic axons. (PMID:14595443)
• netrin-G1 functions as an important component of the NGL-1 receptor to promote TCA outgrowth and that membrane-bound netrins can participate in receiving axonal signaling pathways. (PMID:14595443)
• Interaction between the tripartite NGL-1, netrin-G1 and LAR adhesion complex promotes development of excitatory synapses. (PMID:23986473)
• These data suggest that the proband’s autism may be due to the inheritance of disruptions in both DPP6 and LRRC4C, and may highlight the importance of the netrin G family and potassium channel interacting molecules in neurodevelopmental disorders. (PMID:27759917)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	lrrc4cb	ENSDARG00000016739
danio_rerio	lrrc4ca	ENSDARG00000113411
mus_musculus	Lrrc4c	ENSMUSG00000050587
rattus_norvegicus	Lrrc4c	ENSRNOG00000029798

Paralogs (22): DCN (ENSG00000011465), RTN4R (ENSG00000040608), ASPN (ENSG00000106819), FLRT3 (ENSG00000125848), FLRT1 (ENSG00000126500), LRRC4 (ENSG00000128594), LRRC4B (ENSG00000131409), PODNL1 (ENSG00000132000), LRTM1 (ENSG00000144771), LRRTM1 (ENSG00000162951), LRRC15 (ENSG00000172061), PODN (ENSG00000174348), LRRTM4 (ENSG00000176204), BGN (ENSG00000182492), LRRC19 (ENSG00000184434), FLRT2 (ENSG00000185070), GP1BA (ENSG00000185245), RTN4RL1 (ENSG00000185924), RTN4RL2 (ENSG00000186907), NYX (ENSG00000188937), LRRC66 (ENSG00000188993), LRRTM3 (ENSG00000198739)

Protein

Protein identifiers

Leucine-rich repeat-containing protein 4C — Q9HCJ2 (reviewed: Q9HCJ2)

Alternative names: Netrin-G1 ligand

All UniProt accessions (2): Q9HCJ2, E9PLP4

UniProt curated annotations — full annotation on UniProt →

Function. May promote neurite outgrowth of developing thalamic neurons.

Subunit / interactions. Interacts with NTNG1 and WHRN.

Subcellular location. Postsynaptic cell membrane.

Tissue specificity. Highly expressed in the cerebral cortex, including frontal, parietal and occipital lobes. Putamen, amygdala, hippocampus and medulla oblongata show moderate expression. Caudate nucleus and thalamus express small amounts, whereas other brain regions show very weak or no expression.

Domain organisation. The LRR region is both necessary and sufficient for the interaction with NTNG1.

RefSeq proteins (2): NP_001245348, NP_065980 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000372	LRRNT	Domain
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050541	LRR_TM_domain-containing	Family

Pfam: PF00560, PF07679, PF13855

UniProt features (49 total): strand 22, repeat 9, turn 7, domain 3, helix 2, signal peptide 1, chain 1, region of interest 1, modified residue 1, disulfide bond 1, transmembrane region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
3ZYJ	X-RAY DIFFRACTION	3.25

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCJ2-F1	75.92	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 631

Disulfide bonds (1): 375–426

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 107 (showing top): MODULE_255, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MODULE_317, GOBP_NEUROGENESIS, GOBP_CELL_CELL_SIGNALING, GOBP_CELL_CELL_ADHESION, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_SYNAPTIC_SIGNALING, GOBP_REGULATION_OF_NEURON_PROJECTION_DEVELOPMENT, GOBP_CELL_PROJECTION_ORGANIZATION, RIGGI_EWING_SARCOMA_PROGENITOR_UP, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, SENESE_HDAC3_TARGETS_DN, GOCC_POSTSYNAPSE

GO Biological Process (3): regulation of axonogenesis (GO:0050770), modulation of chemical synaptic transmission (GO:0050804), synaptic membrane adhesion (GO:0099560)

GO Molecular Function (3): cell adhesion molecule binding (GO:0050839), cell-cell adhesion mediator activity (GO:0098632), protein binding (GO:0005515)

GO Cellular Component (8): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), membrane (GO:0016020), Schaffer collateral - CA1 synapse (GO:0098685), postsynaptic density membrane (GO:0098839), glutamatergic synapse (GO:0098978), synapse (GO:0045202), postsynaptic membrane (GO:0045211)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell-cell adhesion	2
synapse	2
axonogenesis	1
regulation of neuron projection development	1
regulation of anatomical structure morphogenesis	1
chemical synaptic transmission	1
regulation of trans-synaptic signaling	1
synapse organization	1
protein binding	1
cell adhesion mediator activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1
postsynaptic density	1
postsynaptic membrane	1
postsynaptic specialization membrane	1
cell junction	1
synaptic membrane	1
postsynapse	1

Protein interactions and networks

STRING

1572 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRC4C	NTNG2	Q96CW9	999
LRRC4C	NTNG1	Q9Y2I2	999
LRRC4C	WHRN	Q9P202	898
LRRC4C	DLG4	P78352	897
LRRC4C	MYO15A	Q9UKN7	709
LRRC4C	ADGRV1	Q8WXG9	671
LRRC4C	MPP1	Q00013	649
LRRC4C	USH1G	Q495M9	649
LRRC4C	PTPRS	Q13332	631
LRRC4C	NLGN1	Q8N2Q7	618
LRRC4C	NRXN1	Q9ULB1	618
LRRC4C	CDKL5	O76039	608
LRRC4C	USH2A	O75445	574
LRRC4C	NTN1	O95631	524
LRRC4C	LRRTM1	Q86UE6	488

IntAct

89 interactions, top by confidence:

A	B	Type	Score
LRRC4C	DOLK	psi-mi:“MI:0915”(physical association)	0.740
NTNG1	LRRC4C	psi-mi:“MI:0407”(direct interaction)	0.620
LRRC4C	NTNG1	psi-mi:“MI:0407”(direct interaction)	0.620
BRICD5	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
CMTM5	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
SNAP47	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
GJB2	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
CLDN19	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
SMIM1	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
SERTM1	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
CLEC1A	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
LHFPL5	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
TWSG1	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
BMP10	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
MIP	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560
AGTRAP	LRRC4C	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (98): LRRC4B (Affinity Capture-MS), LRRC4 (Affinity Capture-MS), VLDLR (Affinity Capture-MS), SULF1 (Affinity Capture-MS), SULF2 (Affinity Capture-MS), DVL2 (Affinity Capture-MS), SBF1 (Affinity Capture-MS), UBE2S (Affinity Capture-MS), NCOA5 (Affinity Capture-MS), DOLK (Affinity Capture-MS), NOB1 (Affinity Capture-MS), FSTL1 (Affinity Capture-MS), SLC39A11 (Affinity Capture-MS), BTBD1 (Affinity Capture-MS), MTMR1 (Affinity Capture-MS)

ESM2 similar proteins: C0STK7, C3YZ59, O00206, O15455, O42235, O60938, O62702, O93233, P58727, Q0PV50, Q2V898, Q45R42, Q58A48, Q5BK65, Q5M7S9, Q5TJ59, Q62192, Q65YW8, Q65Z91, Q68Y56, Q6AXL3, Q6DF55, Q6R5N8, Q6R5P0, Q7Z2Q7, Q80X72, Q8BMT4, Q8BZT5, Q8C031, Q8N6Y2, Q8R5M3, Q8SPE8, Q8SPE9, Q965M2, Q99467, Q99MB1, Q99PH1, Q9CQ76, Q9CXD9, Q9DE66

Diamond homologs: A0N0X6, A1KZ92, A2A8L5, A3KNN3, A4IFW2, A4IGL7, A4IIW9, A6H793, A7MBJ4, A8WGA3, B0BNK7, B0V2N1, B3MH43, B3NS99, B4GBH0, B4HNW4, B4KPU0, B4MR28, B4P5Q9, B4QC63, D2HFT7, D3YXG0, D4A1J9, D4ABX8, E9Q7T7, F1MLX5, F1NWE3, F1NY98, O55005, O60469, O75325, O89026, O94779, O95428, P0C6S8, P0C7J6, P10586, P16621, P59034, P59035

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CDKL5	unknown	LRRC4C	phosphorylation
NTNG1	“up-regulates activity”	LRRC4C	binding
LRRC4C	“up-regulates activity”	DLG4	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

70 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	62
Likely benign	5
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

5533 predictions. Top by Δscore:

Variant	Effect	Δscore
11:40116331:CAGT:C	acceptor_gain	1.0000
11:40286238:A:AC	donor_gain	1.0000
11:40286239:C:CC	donor_gain	1.0000
11:40319623:CTTA:C	donor_loss	1.0000
11:40319624:TTA:T	donor_loss	1.0000
11:40319625:TA:T	donor_loss	1.0000
11:40319626:A:AC	donor_gain	1.0000
11:40319626:ACCTT:A	donor_loss	1.0000
11:40319627:C:A	donor_loss	1.0000
11:40319627:C:CC	donor_gain	1.0000
11:40319627:CCTTA:C	donor_gain	1.0000
11:40319717:TATAC:T	acceptor_gain	1.0000
11:40319719:TAC:T	acceptor_gain	1.0000
11:40319720:AC:A	acceptor_gain	1.0000
11:40319720:ACCT:A	acceptor_loss	1.0000
11:40319721:CC:C	acceptor_gain	1.0000
11:40319722:C:CC	acceptor_gain	1.0000
11:40319722:C:CG	acceptor_loss	1.0000
11:40319723:T:C	acceptor_loss	1.0000
11:40325957:AAAG:A	donor_gain	1.0000
11:40648137:CTTA:C	donor_loss	1.0000
11:40648139:TA:T	donor_loss	1.0000
11:40648140:A:AC	donor_gain	1.0000
11:40648140:A:AT	donor_loss	1.0000
11:40648141:C:CC	donor_gain	1.0000
11:40648141:CCTG:C	donor_gain	1.0000
11:40648274:AACTC:A	acceptor_gain	1.0000
11:40648275:ACTC:A	acceptor_gain	1.0000
11:40648276:CTC:C	acceptor_gain	1.0000
11:40648276:CTCC:C	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000000042 (11:40527643 T>G), RS1000003613 (11:41182926 G>A), RS1000004912 (11:40508162 G>A), RS1000007690 (11:41389294 G>A,T), RS1000010453 (11:40591202 C>A,T), RS1000010723 (11:40935413 G>A), RS1000011794 (11:40295677 T>C), RS1000012628 (11:40178710 C>A,T), RS1000017249 (11:40932007 G>A), RS1000018791 (11:40667301 A>G), RS1000019555 (11:41320737 G>A), RS1000033720 (11:40214681 A>G), RS1000034971 (11:40457717 C>T), RS1000036259 (11:41022203 T>C), RS1000036443 (11:40389303 G>T)

Disease associations

OMIM: gene MIM:608817 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

26 associations (top):

Study	Trait	p-value
GCST000698_1	Osteoporosis-related phenotypes	9.000000e-07
GCST001419_10	Temperament (bipolar disorder)	6.000000e-06
GCST003229_1	Survival in colorectal cancer	3.000000e-06
GCST003262_382	Post bronchodilator FEV1	1.000000e-06
GCST003264_1612	Post bronchodilator FEV1/FVC ratio	1.000000e-06
GCST003997_48	Myopia	9.000000e-66
GCST004863_27	Mosquito bite size	6.000000e-06
GCST005714_5	Cerebrospinal fluid beta-site APP cleaving enzyme levels	9.000000e-06
GCST006291_130	Spherical equivalent or myopia (age of diagnosis)	2.000000e-44
GCST006585_2583	Blood protein levels	2.000000e-08
GCST007008_5	Cerebrospinal fluid p-tau levels	9.000000e-07
GCST007323_33	Risk-taking tendency (4-domain principal component model)	2.000000e-08
GCST007325_79	General risk tolerance (MTAG)	7.000000e-10
GCST007327_126	Smoking status (ever vs never smokers)	3.000000e-09
GCST007743_25	Iris color (L* coordinate)	4.000000e-06
GCST008477_21	Emphysema annual change measurement in smokers (adjusted lung density)	9.000000e-06
GCST009203_9	Cerebellum cortex volume	6.000000e-06
GCST009646_4	Diastolic blood pressure response to thiazide and thiazide-like diuretics in hypertension	5.000000e-08
GCST009962_14	High myopia	1.000000e-14
GCST010002_235	Refractive error	1.000000e-175
GCST011831_1	Pediatric central nervous system tumors (early onset)(pleiotropy)	8.000000e-07
GCST012017_3	Mastocytosis (KIT D816V positive)	1.000000e-06
GCST012400_11	Low myopia vs hyperopia	6.000000e-10
GCST012402_33	Low myopia	3.000000e-10
GCST012490_178	Femur bone mineral density x serum urate levels interaction	3.000000e-08
GCST013216_1	Order dimension in obsessive compulsive disorder	6.000000e-06

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0004365	personality trait
EFO:0000714	survival time
EFO:0004314	forced expiratory volume
EFO:0004713	FEV/FVC ratio
EFO:0008378	mosquito bite reaction size measurement
EFO:0009179	beta-secretase 1 measurement
EFO:0004847	age at onset
EFO:0004763	p-tau measurement
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:0009764	eye colour measurement
EFO:0007626	emphysema imaging measurement
EFO:0006945	diastolic blood pressure change measurement
EFO:0004531	urate measurement
EFO:0007802	obsessive-compulsive symptom measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, decreases expression	4
trichostatin A	increases expression, affects cotreatment	3
Vorinostat	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Silicon Dioxide	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
bisphenol A	decreases methylation	1
decabromobiphenyl ether	increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
sodium arsenite	increases expression	1
tetrabromobisphenol A	increases expression	1
aflatoxin B2	increases methylation	1
tetrachlorodian	increases expression	1
mesotrione	affects methylation, increases abundance	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, decreases expression, increases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1
Allergens	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Carbamazepine	affects expression	1
Formaldehyde	decreases expression	1
Herbicides	affects methylation, increases abundance	1
Triclosan	increases expression	1
Aflatoxin B1	affects methylation, decreases methylation	1
Particulate Matter	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.